PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
15.19%
ROE below 50% of CRVO's 191.90%. Michael Burry would look for signs of deteriorating business fundamentals.
-724.25%
Negative ROA while CRVO stands at 0.00%. John Neff would check for structural inefficiencies or mispriced assets.
206.70%
ROCE 1.25-1.5x CRVO's 171.51%. Bruce Berkowitz would confirm if the firm’s capital structure drives superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.